Drugs / Mesothelin-targeted T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02792114 | Jun 2016 → Jun 2027 expected | Her2-receptor negative breast cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mesothelin-targeted T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02792114 ↗ |
| Modality | Cell therapy | “Mesothelin-Specific Chimeric Antigen Receptor-Positive T Cells” NCT02792114 ↗ |
| Route | Intravenous | “infused via intravenous catheter or central line” NCT02792114 ↗ |